These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 21396117)

  • 1. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
    Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
    Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.
    Burga LN; Tung NM; Troyan SL; Bostina M; Konstantinopoulos PA; Fountzilas H; Spentzos D; Miron A; Yassin YA; Lee BT; Wulf GM
    Cancer Res; 2009 Feb; 69(4):1273-8. PubMed ID: 19190334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
    Strecker TE; Shen Q; Zhang Y; Hill JL; Li Y; Wang C; Kim HT; Gilmer TM; Sexton KR; Hilsenbeck SG; Osborne CK; Brown PH
    J Natl Cancer Inst; 2009 Jan; 101(2):107-13. PubMed ID: 19141783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors.
    Zhang C; Mori M; Gao S; Li A; Hoshino I; Aupperlee MD; Haslam SZ; Xiao H
    Cancer Res; 2010 Dec; 70(24):10224-33. PubMed ID: 21159643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
    Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
    Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
    Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
    J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
    J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
    Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
    Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
    BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.
    Bade LK; Goldberg JE; Dehut HA; Hall MK; Schwertfeger KL
    J Cell Sci; 2011 Sep; 124(Pt 18):3106-17. PubMed ID: 21868365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers.
    Zvelebil M; Oliemuller E; Gao Q; Wansbury O; Mackay A; Kendrick H; Smalley MJ; Reis-Filho JS; Howard BA
    Breast Cancer Res; 2013 Mar; 15(2):R25. PubMed ID: 23506684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into lineage restriction of mammary gland epithelium using parity-identified mammary epithelial cells.
    Chang TH; Kunasegaran K; Tarulli GA; De Silva D; Voorhoeve PM; Pietersen AM
    Breast Cancer Res; 2014 Jan; 16(1):R1. PubMed ID: 24398145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 regulates human mammary stem/progenitor cell fate.
    Liu S; Ginestier C; Charafe-Jauffret E; Foco H; Kleer CG; Merajver SD; Dontu G; Wicha MS
    Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1680-5. PubMed ID: 18230721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
    Ma Y; Katiyar P; Jones LP; Fan S; Zhang Y; Furth PA; Rosen EM
    Mol Endocrinol; 2006 Jan; 20(1):14-34. PubMed ID: 16109739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
    Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.
    Muraoka-Cook RS; Caskey LS; Sandahl MA; Hunter DM; Husted C; Strunk KE; Sartor CI; Rearick WA; McCall W; Sgagias MK; Cowan KH; Earp HS
    Mol Cell Biol; 2006 Sep; 26(17):6412-24. PubMed ID: 16914727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.